- Zacks Small Cap Research•3 days ago
On October 13, 2016 Resverlogix Corp. (RVX.TO) held a research and development update for shareholders, investors and analysts in New York City. Several key opinion leaders (KOLs) and Resverlogix management team members spoke at the event providing an update on the latest thoughts on diabetes, chronic kidney disease (CKD) and how these co-morbidities impact cardiovascular disease. The discussion and focused on the company’s trials and progress for Resverlogix’s lead compound, apabetalone.
- PR Newswire•14 days ago
TORONTO, Oct. 6, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has rescheduled its Annual and Special Meeting of Shareholders ...
Resverlogix Corp. (RVX.TO)
Toronto - Toronto Delayed Price. Currency in CAD
|Day's Range||1.93 - 2.01|
|52wk Range||1.10 - 2.52|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-7.26|
|Avg Vol (3m)||43,825|
|Dividend & Yield||N/A (N/A)|